A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy (ADHAND)

LEO Pharma

Status and phase: Enrolling; Phase 3

Conditions: Atopic Dermatitis; Atopic Hand Eczema

Treatments: Drug: Placebo; Drug: Tralokinumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT05958407

U1111-1285-7014 (Other Identifier)

2022-502653-34-00 (Other Identifier)

LP0162-2328

Details and patient eligibility

About

The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life.

The trial will last for up to 40 weeks. There will be up to 15 visits, 3 of which will be conducted by phone. The first part of the trial is called a screening period and will last up to 4 weeks. For the first 16 weeks after screening, trial participants will receive either tralokinumab or dummy injections every two weeks. After the first 16 weeks, all trial participants will receive tralokinumab injections every two weeks for 16 weeks. The last part of the trial is a period of 4 weeks after the end of treatment period, where trial participants are off the drug for safety follow-up.

Enrollment: 402 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18 years or above at screening
• Diagnosis of atopic dermatitis (AD) as by the Hanifin and Rajka (1980) criteria for AD
• History of AD for ≥1 year
• Presence of atopic hand eczema (AHE) that has persisted for more than 3 months or returned twice or more within the last 12 months, with avoidance of any known and relevant irritants and allergens
• AD involvement of at least one body location other than the hands and wrists at screening
• An Investigator's Global Assessment AHE score of 3 or 4 (moderate to severe) at screening and baseline
• A HESD itch score (weekly average) of ≥4 at baseline
• Subjects who have a documented recent history (within 12 months before the screening visit) of inadequate response to treatment of AHE with topical prescription medications or for whom topical treatments are otherwise medically inadvisable (e.g., due to important side effects or safety risks)

Exclusion criteria

• Subjects must not enter the trial if they have active subtypes of hand eczema other than AHE that are considered to be the predominant cause of the current hand eczema including:

  • Active irritant contact dermatitis
  • Active allergic contact dermatitis
  • Active protein contact dermatitis/contact urticaria
  • Active hyperkeratotic hand eczema
  • Active vesicular hand eczema (pompholyx)

• Active dermatologic conditions that may confound the diagnosis of AD or AHE, or that would interfere with the assessment of treatment

• Use of tanning beds or phototherapy (e.g., UVB, UVA1, PUVA), or Grenz ray therapy on the hands or wrists within 28 days prior to baseline or use of bleach baths on the hands or wrists within 7 days prior to baseline

• Treatment with systemic immunosuppressive/immunomodulating drugs and/or systemic corticosteroids within 28 days prior to baseline

• Treatment with topical corticosteroids, topical calcineurin inhibitors, topical phosphodiesterase 4 inhibitors, or topical Janus kinase inhibitors within 7 days prior to baseline

• Receipt of any marketed biological therapy (i.e. immunoglobulin, anti immunoglobulin E) including dupilumab or investigational biologic agents 3 to 6 months prior to baseline

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

402 participants in 2 patient groups, including a placebo group

Tralokinumab

Experimental group

Description:

Tralokinumab is administered for 32 weeks (16 weeks double-blinded period + 16 weeks open-label period)

Treatment:

Drug: Tralokinumab

Placebo + tralokinumab

Placebo Comparator group

Description:

Placebo is administered for 16 weeks (double-blinded period) prior to roll-over to a 16 weeks open-label period where tralokinumab is administered

Treatment:

Drug: Placebo